Articles related to Urology

HER2-Directed ADCs in Gastric Cancer Several antibody-drug conjugates (ADCs) have recently received approval for use in treating a range of solid cancers. This poses difficulties when handling a variety of adverse treatment-related events, some of which can take practitioners into uncharted area. After viewing this CME activity, medical oncologists, pulmonologists, urologists, pathologists, oncology NPs, PAs, oncology nurses, oncology pharmacists, and other HCPs caring for patients with solid tumors should be able to describe the elements of an antibody-drug conjugate (ADC) that may cause adverse events (AEs), identify AEs that result in treatment interruption or discontinuation, and suggest a strategy for managing the key AEs.

In a study of 37,887 men 50 to 60 years old, those with PSA of >= 3 ng/ml underwent MRI imaging of the prostate and were randomized to systematic biopsy plus targeted biopsy or MRI-targeted biopsy only. MRI-directed targeted biopsy reduced the risk of overdiagnosis by half but did delay detection of intermediate-risk tumors in a small proportion of patients.

The study included 1,306 patients (darolutamide: 651, placebo: 655), with 86.1% having metastatic disease at the time of diagnosis. At the primary analysis’s data cutoff date (October 25, 2021), the risk of death in the darolutamide group was 32.5% lower than in the placebo group. Adverse events were comparable in both groups, and the most common adverse events (occurring in 10% of patients) were most common during the overlapping docetaxel treatment period in both groups.

These specialties had the highest proportion of doctors still making student loan payments, per the 2022 Medscape report: Emergency Medicine (31%) Physical Medicine & Rehabilitation (31%) Pediatrics (31%) Neurology (28%) Otolaryngology (28%) Family Medicine (28%) For the least debt-burdened: Pulmonary Medicine (10%) Public Health & Preventive Medicine (11%) Rheumatology (12%) Diabetes & Endocrinology (15%) Dermatology (16%) Cardiology (16%)

MDLinx compiled a reading list of captivating books that have nothing to do with medicine—but might just help physicians realize some things about their work — and life.

In this cohort analysis, which included male patients examined at 128 US Veterans Health Administration facilities between 2005 (n = 4,678,412) and 2019 (n = 5,371,701), facilities with greater rates of prostate-specific antigen screening showed lower rates of eventual metastatic prostate cancer incidence.